MARKETING ANALYSIS OF THE COST OF COUNTERFEIT MEDICINES IN THE PHARMACEUTICAL MARKET OF RUSSIA

  • Authors: Levchuk Y.1
  • Affiliations:
    1. Курский государственный медицинский университет
  • Issue: Vol 11, No 1 (2022): XVI МЕЖДУНАРОДНАЯ НАУЧНО-ПРАКТИЧЕСКАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ-МЕДИКОВ
  • Pages: 50-51
  • Section: Менеджмент в здравоохранении
  • URL: https://new.vestnik-surgery.com/index.php/2415-7805/article/view/7480

Cite item

Abstract

The presence of counterfeit pharmaceutical products is one of the threats to the development of the pharmaceutical market in Russia. The reasons for the introduction of drugs of inadequate quality (substandard, falsified and counterfeit) are the high cost of original drugs, the imperfection of the legislative framework, high tariffs for the release of drugs to the market and others.

Full Text

Relevance. The presence of counterfeit pharmaceutical products is one of the threats to the development of the pharmaceutical market in Russia. The reasons for the introduction of drugs of inadequate quality (substandard, falsified and counterfeit) are the high cost of original drugs, the imperfection of the legislative framework, high tariffs for the release of drugs to the market and others.
The purpose of the study: marketing analysis of the cost of counterfeit drugs identified in the pharmaceutical market of Russia in 2021.
Research methods: logical, comparative, content analysis.
Research materials: informational letters of the Federal Service for Supervision of Healthcare of the Russian Federation for 2021, official websites of online pharmacies of the country (Apteka.ru ; Zdravcity; SberApteka; April).
The results of the study. In 2021, 11 trade names of counterfeit medicines (LP) were identified in the pharmaceutical market of Russia, the cost of which varies from 1,646.50 rubles. (Essentiale ® N) up to 124879.00 rubles. (Kadsila).
Thus, the group of counterfeit products does not include LP of a low price category. Due to the high amplitude of prices during the logical analysis, three groups of LP were identified by cost: medium price category (up to 8000 rubles), high (from 8000 to 16000 rubles) and very high (over 16000 rubles) (Table 1).

Table 1 - Price groups of counterfeit LP

Price segment

Trade name

Pharmacotherapeutic group

Average price for 1 package, rub.

Middle price segment

Essentiale ® N

Hepatoprotective agent

1646,50

Seroquel XR

Antipsychotic (neuroleptic) agent

2898,50

Xarelto ® , 20 mg

Xarelto ® , 2.5 mg

Xarelto ® , 15 mg

Direct Factor Xa inhibitors

3064,50

3737,50

3120,00

Adenuric ®

Anti-gouty agent, xanthine oxidase inhibitor

3172,00

High price segment

Prolia ®

Drugs for the treatment of bone diseases are other drugs that affect the structure and mineralization of bone.

13330,25

Aklasta

Bone resorption inhibitor - bisphosphonate

15064,75

Mirena ®

Gestagen

15236,67

Very high price segment

Phazlodex

Antitumor agent, antiestrogen

36696,00

Simzia ®

MIBP-monoclonal antibodies

55864,00

Kadsila

Antitumor agent - monoclonal antibodies

124879,00

No information available

Nexium

Proton Pump inhibitor

-

The analysis showed that the group of counterfeit drugs withdrawn from circulation in the pharmaceutical market of Russia in 2021 is represented by expensive hepatoprotective, neuroleptic, antithrombic, anti-gouty, monoclonal antibodies, correctors of bone and cartilage tissue metabolism, progestogens, antitumor drugs and proton pump inhibitors. Considering that the main reasons for the seizure are violation of civil legislation and labeling in Turkish or Ukrainian, it can be concluded that the directed production and import of counterfeit LP of a high price category.

 
×

About the authors

Yuliya Levchuk

Курский государственный медицинский университет

Author for correspondence.
Email: yuliya.levchuk.11@yandex.ru

студент

Russian Federation

References

  1. Олейникова, Т.А. Мониторинг фальсифицированных, недоброкачественных и контрафактных лекарственных препаратов на фармацевтическом рынке России: монография / Т.А. Олейникова. – Курск: КГМУ, 2020. – 172 с.
  2. Макарова, Ю.А. Актуальные проблемы противодействия поставкам фальсифицированных, недоброкачественных и контрафактных лекарственных средств / Ю.А. Макарова // Современные проблемы права, экономики и управления. – 2016. – Т. 3, № 2. – С. 168 – 175.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies